Market Trends AbbVie gets FDA approval for antibiotic treatment Emblaveo (ABBV:NYSE)By admin8996erT0allFebruary 7, 2025 hapabapaAbbVie (NYSE:ABBV) said it has received FDA approval for its intravenous antibiotic treatment Emblaveo. The FDA approved Emblaveo, a combination…
Market Trends AbbVie Non-GAAP EPS of $2.16 misses by $0.10, revenue of $15.1B beats by $270M (NYSE:ABBV)By admin8996erT0allJanuary 31, 2025 AbbVie press release (NYSE:ABBV): Q4 Non-GAAP EPS of $2.16 misses by $0.10. Revenue of $15.1B (+5.6% Y/Y) beats by $270M.…
Market Trends AbbVie, AbCellera expand collaboration into T-cell engagersBy admin8996erT0allJanuary 13, 2025 AbbVie (NYSE:ABBV) and AbCellera (NASDAQ:ABCL) have expanded their collaboration to include the discovery of T-cell engagers for the treatment of…
